Background
Methods
Eligibility criteria
Treatment plans
Toxicity and response evaluation
Statistical analyses
Results
Patient characteristics
Variables | Startification | Over all | BDca | GBca |
---|---|---|---|---|
Spieces of cancer | 42 | 27 | 15 | |
Sex | (male/female) | (24/18) | (17/10) | (7/8) |
Age | 66.5 ± 7.5 | 64.8 ± 8.2 | 69.5 ± 4.7 | |
ECOG PS | (0/1/2) | (36/4/2) | (22/4/1) | (14/0/1) |
Disease Status | (unresectable/postoperative recurrence) | (26/16) | (15/12) | (11/4) |
Disease extension | locally advanced (primary) | 26 | 15 | 11 |
local recurrence | 7 | 7 | 0 | |
liver metastasis | 9 | 4 | 5 | |
lung metastasis | 4 | 3 | 1 | |
lymphnode metastasis | 11 | 4 | 7 | |
miscellaneous metastasis | 5 | 5 | 0 | |
Tumor marker | carcinoembryonic antigen (CEA) | 16.7 ± 60.7 | 6.4 ± 17.2 | 36.7 ± 100.5 |
CA19-9 | 3035.5 ± 9507.6 | 4495.3 ± 11688.8 | 407.9 ± 587.2 | |
Previous chemotherapy | (yes/no) | (4/38) | (3/24) | (1/14) |
Response and time-to-event measures
Over all
| ||||||
---|---|---|---|---|---|---|
CR | PR | NC | PD | Response Rate (%)95%C.I. CR+PR/TOTAL | Clinical Response (%)95%C.I. CR+PR+NC/TOTAL | |
Over all | 0 | 18 | 13 | 11 | 42.9 (27.7–59.0) | 73.8 (58.0–86.2) |
BDca | 0 | 11 | 10 | 6 | 40.7 (22.4–61.2) | 77.8 (57.8–91.4) |
GBca | 0 | 7 | 3 | 5 | 46.7 (21.1–73.5) | 66.7 (38.4–88.2) |
Primary or local recurrence
| ||||||
CR | PR | NC | PD | Response Rate (%)95%C.I. CR+PR/TOTAL | Clinical Response (%)95%C.I. CR+PR+NC/TOTAL | |
Over all | 0 | 14 | 8 | 6 | 50.0 (30.6–69.4) | 78.6 (59.0–91.7) |
BDca | 0 | 9 | 6 | 3 | 50.0 (26.0–74.0) | 83.3 (58.6–96.5) |
GBca | 0 | 5 | 2 | 3 | 50.0 (18.6–81.4) | 70.0 (34.7–93.5) |
Metastatic lesion
| ||||||
CR | PR | NC | PD | Response Rate (%)95%C.I. CR+PR/TOTAL | Clinical Response (%)95%C.I. CR+PR+NC/TOTAL | |
Over all | 0 | 10 | 12 | 9 | 32.3 (16.7–51.4) | 71.0 (52.0–85.8) |
BDca | 0 | 6 | 9 | 5 | 30.0 (11.8–54.3) | 75.0 (50.9–91.4) |
GBca | 0 | 4 | 3 | 4 | 36.4 (10.8–69.3) | 66.7 (30.7–89.2) |
Toxicity
Hematological Toxicity | Gr1 | Gr2 | Gr3 | Gr4 | ≧Gr3 (%) | Over all (%) |
---|---|---|---|---|---|---|
anemia | 0 | 11 | 0 | 0 | 0 (0) | 11 (26.2) |
leukopenia | 0 | 1 | 0 | 0 | 1 (0) | 1 (2.3) |
thrombocytopenia | 0 | 2 | 3 | 0 | 3 (7.1) | 5 (11.9) |
Non-hematological Toxicity | Gr1 | Gr2 | Gr3 | Gr4 | ≧Gr3 (%) | Over all (%) |
nausea | 3 | 4 | 1 | 0 | 1 (2.3) | 8 (19.0) |
vomiting | 1 | 1 | 3 | 0 | 1 (2.3) | 5 (11.9) |
appetite loss | 0 | 0 | 6 | 0 | 6 (14.3) | 6 (14.3) |
oral mucositis | 0 | 4 | 0 | 0 | 0 (0) | 4 (9.5) |
taste disturbance | 0 | 1 | 0 | 0 | 1 (2.3) | 1 (2.3) |
upper GI tract bleeding | 0 | 1 | 0 | 0 | 0 (0) | 1 (2.3) |
diarrhea | 1 | 0 | 0 | 0 | 0 (0) | 1 (2.3) |
general fatigue | 0 | 1 | 1 | 0 | 1 (2.3) | 2 (4.7) |
jaundice | 0 | 0 | 4 | 0 | 4 (9.5) | 4 (9.5) |
serum AST/ALT level elevation | 0 | 4 | 1 | 0 | 1 (2.3) | 1 (2.3) |
Serum creatinine level elevation | 0 | 6 | 0 | 0 | 0 (0) | 6 (14.3) |
Prognostic factors related survival and TTF
Over all survival Time to treatment Failure | ||||||
---|---|---|---|---|---|---|
Stratification | Hazard ratio | p-value | 95% C.I. | Hazard ratio | p-value | 95% C.I. |
Sex (male/female) | 0.123 | 0.0128 | 0.024–0.640 | 0.225 | 0.0095 | 0.073–0.695 |
Age (≧69/<69) | 0.634 | 0.6082 | 0.111–3.692 | 2.380 | 0.2269 | 0.583–9.713 |
ECOG PS (PS0/PS1/PS2) | 0.016 | 0.0015 | 0.001–0.259 | 0.230 | 0.0007 | 0.001–0.152 |
Species of tumor (BDca/GBca) | 0.095 | 0.0198 | 0.013–0.688 | 0.001 | 0.0411 | 0.0856–0.943 |
Disease status (locally advanced/postoperative recurrence) | 0.121 | 0.0179 | 0.021–0.695 | 0.802 | 0.7388 | 0.001–0.152 |
Radiation (yes/no) | 8.369 | 0.1491 | 0.467–150.112 | 0.603 | 0.4586 | 0.158–2.299 |
Previous chemotherapy (yes/no) | 0.143 | 0.0255 | 0.016–1.241 | 0.495 | 0.4086 | 0.094–2.622 |
Initial CEA level (≧1 UL/<1 UL) | 1.098 | 0.9053 | 0.234–5.160 | 2.453 | 0.1267 | 0.775–7.763 |
Interval decreasing CEA level (yes/no) | 0.224 | 0.2859 | 0.014–3.499 | 1.734 | 0.5968 | 0.260–11.568 |
Initial CA19-9 level (≧5 UL/<5 UL) | 0.078 | 0.0255 | 0.014–3.499 | 1.734 | 0.5968 | 0.260–11.568 |
Interval decreasing CA19-9 level(yes/no) | 1.449 | 0.7667 | 0.125–16.774 | 0.326 | 0.2600 | 0.047–2.290 |
Cost benefit
Outpatient-basis or home | Inpatient-basis |
---|---|
At home malignant tumor | Basic admission fee 472,900 yen |
Administration fee 25,000 yen | Local infusion technical fee (addition to minute infusion) 46,200 yen |
Portable infuser pump | |
using fee 15,000 yen | Diet 63,600 yen |
Medication | Medication |
CDDP 20,000 yen | CDDP 20,000 yen |
5-FU 15,000 yen | 5-FU 15,000 yen |
Tumor marker 5,000 yen | Tumor marker 5,000 yen |
Other laboratory test 8,400 yen | Other laboratory test 8,400 yen |
Imaging diagnosis 15,000 yen | Imaging diagnosis 15,000 yen |
(antiemeric drug 16,000 yen) | (antiemeric drug 16,000 yen) |
Total 103,600 (119,600) yen | Total 646,300 (662,300) yen |
Discussion
Author (published year) | Number of Patients | Species of cancer | Regimen | RR (%) | MST (days) | mTTF (days) | Adverse effects (≧Gr3) | Treatment related death |
---|---|---|---|---|---|---|---|---|
Ishii(2004) | 21 | GBca | CEF(CDDP/5-FU/epirubicin) | 33.3 | 177* | - | hematological toxicity (52.3%) | none |
25 | GBca | FAM(5-FU/Doxorubicin/Mitomycin) | 7.1 | - | hematological toxicity (20%) | none | ||
Lee (2004) | 4 | BDca | Gemsitabine/CDDP | 50 | 270 | 150 | thrombocytopenia (75%) | none |
Doval(2004) | 30 | GBca | Gemsitabine/CDDP | 36.6 | 140 | 126 | nausea/vomiting (16%) | 2 |
Malik(2003) | 11 | GBca | Gemsitabine/CDDP | 64 | 294 | 196 | anemia (45%) | none |
Knox (2004) | 27 | BDca/CBca | Gemsitabine/5-FU | 33 | 159 | 111 | hematological toxicity (11%) | none |
Malik(2003) | 30 | CBca | Leucovorin/5-FU | 7.5 | 444 | 141 | diarrhea (30%) | 1 |
Kim (2003) | 42 | BDca/CBca | Capesitabine/CDDP | 21.4 | 273 | 111 | leucopenia (20%) | none |